Items Frequency (%)
Trial status
Ongoing
119(46.48 %)
Completed
137(53.52 %)
Trial phase
Phase I
18(7.03 %)
Phase II
20(7.81 %)
Phase III
35(13.67 %)
Phase IV
14(5.47 %)
Bioequivalence
160(62.50 %)
Others
9(3.52 %)
Trial range
China
247(96.48 %)
International
9(3.52 %)
No. of centers
Single-centre trial
181(70.70 %)
Multiple-centre trial
75(29.30 %)
DMC had been establish 16 (6.25 %)
Insurance had been purchased 98(38.28 %)